On June 21, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference (Press release, Kintara Therapeutics, JUN 21, 2022, View Source [SID1234616122]). The conference is being held virtually on June 21 – 22, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Hoffman will be available for one-on-one meetings. For more information, please contact your registered AGP representative or [email protected].

On June 21, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, reported that company management will participate in two upcoming investor conferences in June (Press release, Adicet Bio, JUN 21, 2022, View Source [SID1234616154]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Truist Securities Cell Therapy Symposium, Symposia-cel, June 28, 2022

Chen Schor, President & CEO, will participate in a panel discussion titled, "The Next Cells & Mechanisms to Watch in Oncology" on Tuesday, June 28, 2022, at 11:30 A.M. ET.
Stifel 2022 Virtual Cell Therapy Summit, June 29-30, 2022

Chen Schor, President & CEO, will participate in a panel discussion titled, "Outlining the Potential of New Cell Types and Novel Approaches" on Wednesday, June 29, 2022, at 1:00 P.M. ET.

On June 21, 2022 Ultima Genomics, Inc. and Exact Sciences Corporation (Nasdaq: EXAS) reported that they have entered a long-term supply agreement for Ultima’s next-generation sequencing (NGS) technologies (Press release, Exact Sciences, JUN 21, 2022, View Source [SID1234616123]). Under the terms of the supply agreement, Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other commercially available technologies . The companies also plan to develop one or more of Exact Sciences’ advanced cancer diagnostic tests using Ultima’s sequencing technology. In conjunction with the agreement, Exact Sciences became an investor in Ultima and joined its ongoing early access program for its high-throughput NGS instrument platform, the UG 100. The collaboration is aimed at driving down the high cost of sequencing to improve patient access to genomics-based testing and human health.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Exact Sciences believes access to differentiated and affordable genomics technologies is critical to providing patients better information before diagnosis and across all stages of cancer treatment," said Kevin Conroy, chairman and CEO of Exact Sciences. "Ultima’s mission to drive down the cost of sequencing and increase the use of genomic information supports our goal to provide accurate and affordable testing options across the cancer continuum. This is particularly important for applications like cancer screening, minimal residual disease, and recurrence monitoring, which could lead to millions of tests per year."

"We founded Ultima Genomics with the mission to continuously drive the scale of genomic information. We believe our mission is closely aligned with the goals of our customers, and we look forward to enabling Exact Sciences and others to perform sequencing at a fraction of the cost today," said Gilad Almogy, CEO of Ultima Genomics. "We designed our new sequencing architecture to scale beyond conventional technologies, and are excited to soon make the UG 100, our first instrument using this architecture, commercially available to more customers. In the future, we aim to continuously improve our technology, further drive down costs, and increase the scale of genomic information to improve patient outcomes."

Over the last 5 years, Ultima Genomics has developed a fundamentally new sequencing architecture designed to scale beyond conventional approaches, including completely different flow cell engineering and sequencing chemistry, and machine learning. Ultima is currently in an early access program for the UG 100, its first high-throughput NGS instrument using this new technology architecture.

On June 21, 2022 Rakuten Medical Taiwan, Inc. reported that their ASP-1929 Photoimmunotherapy Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT05265013) has enrolled and treated its first patient (Press release, Rakuten Medical, JUN 21, 2022, View Source [SID1234616139]). This trial is using ASP-1929 photoimmunotherapy based on the Alluminox platform in combination with anti-PD1 therapy in head and neck squamous cell carcinoma to measure patient’s Objective Response Rate (ORR) . The trial will be conducted in 3 medical centers in North Taiwan and 2 medical centers in Central Taiwan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to official cancer registration report, head and neck cancer ranks third in male cancer incidence and fourth in male cancer mortality in Taiwan, with an annual incremental of about 10,000 patients. Majority1 of the patients are males between the ages of 40 and 60. Local recurrence or metastasis is one of the leading causes of death in head and neck cancer patients2, and nearly one-half of recurrent or metastatic patients survive for less than one year3. After receiving treatment, about 40% of patients will still face in situ or local recurrence4.

Dr. Chun Wei Huang from Department of Otorhinolaryngology, Head and Neck Surgery of China Medical University Hospital, who participated in the trial, explained: "Currently patients have limited treatment options after recurrence. When surgery, chemotherapy combined with targeted therapy, radiotherapy, etc. fail to show obvious efficacy in treating head and neck cancer, not only the patients but the medical teams are disappointed. Patients are also prone to losing confidence for further treatment. In addition to this phase II clinical trial, Taiwan is also expected to join more clinical trials. The introduction of more clinical trials presents not only new chances for patients, but also new possibilities for head and neck cancer treatment."

"ASP-1929 has been conditionally approved by the MHLW in Japan and we are establishing more clinical evidence to help cancer patients around the world. The investment of this Phase 2 trial reiterates our long-term commitment in developing Taiwan as the foothold to Asia expansion. The enrollment of first patient also demonstrates the robust momentum and tight-knit collaboration of Rakuten Medical around the globe. We look forward to providing patients with impactful new treatment options as soon as possible," said Mickey Mikitani, Co-CEO of Rakuten Medical, Inc.

Reference
[1] Health Promotion Administration, Ministry of Health and Welfare, 2019 Cancer Registration Report
[2] A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model. Pharmaceutics. 2022 Apr 18;14(4):887. doi:10.3390/pharmaceutics14040887
[3] Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, Licitra L. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2017 May 9;7:72. doi: 10.3389/fonc.2017.00072.
[4] Daniela Alterio, Giulia Marvaso, Annamaria Ferrari, Stefania Volpe, Roberto Orecchia, Barbara Alicja Jereczek-Fossa (2019.) Modern radiotherapy for head and neck cancer

On June 21, 2022 PharmaJet, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, reported that its partner, Nykode Therapeutics announced positive interim results from its phase 2 trial of their novel candidate, VB10.16, in combination with checkpoint inhibitor atezolizumab for treating advanced cervical cancer (Press release, Nykode Therapeutics, JUN 21, 2022, View Source [SID1234616155]). The DNA-based therapeutic cancer vaccine is delivered with the PharmaJet needle-free injection technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HPV is the cause of 630,000 cases of cancers annually1 and HPV16 is the predominant cause. To address this, Nykode Therapeutics is continuing to advance their cervical cancer program with their therapeutic DNA immunotherapy (VB10.16) targeting malignancies caused by the cancer inducing Human Papillomavirus 16 (HPV16). The PharmaJet Needle-free Injection System is proven to increase vaccine effectiveness and in addition was chosen by Nykode for its convenient ease of use.

The interim results demonstrate evidence of anti-tumor activity in a population of heavily pre-treated patients with late-stage cervical cancer. The majority of patients experienced a clinical benefit, and many had durable responses, indicating that VB10.16 may give a meaningful added clinical benefit compared to the existing standard of care treatment in this setting.

Chris Cappello, President and CEO, PharmaJet, commented, "We are encouraged by the phase 2 clinical trial results, and continued expansion of the Nykode clinical trials using our Needle-free Injection System. The number of disease applications for DNA vaccines and therapeutics using our delivery systems continues to grow. This is another example of how our needle-free systems are helping novel DNA technologies move successfully into early and late-stage clinical trials."

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 HPV New Zealand project; HPV and Cancer, View Source